IB Net Payout Yields Model

Tilray: Where The Bears Could Be Wrong

Tilray is generally viewed as an expensive stock with a $7 billion valuation and reported quarterly revenues of only $10 million.
The October 17 legalization of the adult-use market in Canada is a major catalyst for the stock.
Analyst revenue estimates appear low at only $12.8 million for Q4.
The bear thesis could fall apart, if revenues top estimates as expected.
After a hot IPO and first few months of trading, Tilray (TLRY) has come crashing down to $75. Shorts have generally written off the stock due to valuation concerns, but the company has the potential to prove the negative thesis wrong with operations in both Canada and Europe along with some high-profile partnerships.
Read the full article on Seeking Alpha.

Disclosure: No position mentioned. Please review the disclaimer page for more details.


Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

C3.ai: Out Of Steam (Rating Downgrade)

Archer Aviation: Promising Developments